araag2/HINT huggingface dataset:
Clinical trial NCT02289846 (phase 2, status: completed)
Conditions: diabetic gastroparesis
ICD codes: K31.84
Drugs: iw-9179, matching placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is a male or non-pregnant, non-breastfeeding female, and is age 18 years or
             older at the time of the Screening Visit.

          -  Patient has a confirmed diagnosis of type 1 or type 2 diabetes mellitus.

          -  Patient has a diagnosis of DGP with no history or evidence of mechanical obstruction,
             symptoms for at least 3 consecutive months preceding the Screening Visit, and delayed
             gastric emptying of solids documented within 2 years of the Screening Visit.

          -  Patient has a normal EGD either during the Screening Period or within 2 years of the
             Screening Visit, with no evidence of structural or organic disease that may explain
             the patient's gastroduodenal symptoms.

          -  Patient is compliant with eDiary completion.

          -  Patient agrees to refrain from making any new, major lifestyle changes.

          -  Patient is fluent and literate in English.

        Exclusion Criteria:

          -  Patient has a history or current symptoms of any organic or structural disease that,
             in the opinion of the investigator, can cause abdominal pain or discomfort and may
             confound the assessment of DGP symptoms.

          -  Patients with rumination syndrome, cyclic vomiting syndrome, anorexia nervosa, or
             bulimia.

          -  Patient is currently using a gastric electric stimulator or has had endoscopic pyloric
             injections of botulinum toxin within the 6 months prior to the Screening Visit.

          -  Patient has been hospitalized within the 2 months prior to the Screening Visit for
             uncontrolled diabetes mellitus, DGP, or associated malnutrition.

          -  Patient reports significant diarrhea during the four weeks prior to the Screening
             Visit, or more than 2 days during either week of the Pretreatment Period.

          -  Patient has had surgery of the GI tract any time before the Screening Visit, an
             appendectomy or cholecystectomy during the 3 months before the Screening Visit, non-GI
             surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months, or
             other major non-GI surgery during the 30 days before the Screening Visit.

          -  Patient has a history of cancer (resected basal cell or squamous cell carcinoma of the
             skin is acceptable).
Clinical trial NCT02290210 (phase 2, status: completed)
Conditions: gout, hyperuricemia
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021, E79.0
Drugs: urc102 0.25mg, urc102 0.5mg, urc102 1.0mg, urc102 2.0mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with gout

        Exclusion Criteria:

          -  Participated in other clinical study within 12 weeks prior to enrollment, and received
             an investigational product (including placebo)
Clinical trial NCT02291029 (phase 2, status: completed)
Conditions: primary sjögren's syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: cfz533 active - cohort 1, cfz533 placebo- cohort 1, cfz533 active - cohort 2, cfz533 placebo - cohort 2, cfz533 active -cohort 3, cfz533 active - cohort 3
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of primary Sjögren's syndrome

          -  ESSDAI score ≥ 6

        Exclusion Criteria:

          -  Secondary Sjögren's syndrome

          -  Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab,
             belimunab, other immunosuppressives.

          -  At significant risk for thromboembolic event

          -  Clinically significant systemic infection

          -  Significant elevated risk for infection
Clinical trial NCT02291237 (phase 2/phase 3, status: terminated)
Conditions: hypertrophic cardiomyopathy
ICD codes: I42.1, I42.2
Drugs: eleclazine, placebo
SMILES: FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a
             maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis

          -  Exertional symptoms including at least one of the following:

               -  New York Heart Association (NYHA) Class ≥ II dyspnea

               -  Canadian Cardiovascular Society (CCS) Class ≥ II angina

          -  Screening (baseline) peak VO2 < 80% of predicted for age, sex, and weight

          -  Ability to perform an upright treadmill cardiopulmonary exercise test (CPET)

        Key Exclusion Criteria:

          -  Known aortic valve stenosis (moderate or severe)

          -  Known coronary artery disease

          -  Left ventricular systolic dysfunction (ejection fraction < 50%)

          -  Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation)
             within six months prior to screening or such a procedure scheduled to occur during the
             study

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02292719 (phase 2, status: completed)
Conditions: chronic hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: obv/ptv/r, sofosbuvir, ribavirin (rbv)
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          1. Chronic HCV infection prior to study enrollment.

          2. Screening laboratory results from the central clinical laboratory indicating HCV
             genotype 2 or 3 infection only (no mixed genotype).

          3. Absence OR presence of cirrhosis.

          4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular
             carcinoma (HCC)

        Exclusion Criteria:

          1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus
             antibody

          2. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse.

          3. Current enrollment in another clinical study, previous enrolment in this study, or
             previous use of any investigational or commercially available anti-HCV therapy (other
             than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir,
             boceprevir, ABT-450, or ombitasvir (ABT-267).

          4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.

          5. Abnormal lab tests.

          6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose
             partners are pregnant or planning to become pregnant
Clinical trial NCT02293395 (phase 2, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: acetylsalicylic acid, rivaroxaban, clopidogrel, ticagrelor
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Participants, 18 years or older, must have symptoms suggestive of acute coronary
             syndrome (ACS) (angina, or symptoms thought to be equivalent) within 48 hours of
             hospital presentation, or developed ACS while being hospitalized, and has a diagnosis
             of: a) ST segment elevation myocardial infarction (STEMI); b) non-ST-segment elevation
             acute coronary syndrome (NSTE-ACS). However, participant who is 54 years of age or
             younger must also have either diabetes mellitus or a history of a prior myocardial
             infarction (MI), in addition to the presenting ACS event

          -  Participant must be randomized within the screening window of 10 days after hospital
             admission for the index ACS event. Participant should have received acute phase
             treatment for the index ACS, such as intravenous anticoagulant or antiplatelet, and
             are receiving maintenance dual antiplatelet therapy (DAPT) with either clopidogrel
             plus acetyl salicylic acid (ASA), or ticagrelor plus ASA, with the intent to continue
             the treatment with a platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12
             inhibitor) after randomization

          -  Participants must agree to provide a pharmacogenomics deoxyribonucleic acid (DNA)
             sample

        Exclusion Criteria:

          -  Participant has any conditions that, in the opinion of the investigator,
             contraindicates anticoagulant therapy or would have an unacceptable risk

          -  Participant with a prior stroke of any etiology or transient ischemic attack (TIA)

          -  Participant who received thrombolytic therapy as treatment for the index ACS event
             cannot be enrolled in the ticagrelor stratum

          -  Participant has anticipated need for chronic administration of omeprazole or
             esomeprazole concomitantly with clopidogrel

          -  Participant has known allergy or intolerance to ASA or rivaroxaban
Clinical trial NCT02297490 (phase 2, status: terminated)
Conditions: allergic rhinoconjunctivitis, healthy volunteers
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated due to the interim analysis results indicating a weaker correlation
    than anticipated and reported by other study groups.
  
Eligibility criteria:

        Inclusion Criteria:

          -  IgE-mediated seasonal allergic rhinitis/rhinoconjunctivitis with or without allergic
             asthma

          -  positive skin prick test

          -  specific IgE ≥ 0.70 kU/L to mixture of grass pollen allergens

          -  symptom score of at least 4 per day during the week following the peak-pollen count in
             the baseline season

        Exclusion Criteria:

          -  undergone previous specific immunotherapy with grass pollen allergens in any
             formulation less than 5 years prior to the screening date

          -  currently undergoing any sort of immunotherapy, or has ever undergone specific
             immunotherapy with unknown allergen

          -  allergens which are expected to interfere with the grass pollen season

          -  uncontrolled or partly controlled asthma

          -  patients with contraindications for SIT
Clinical trial NCT02299089 (phase 2, status: completed)
Conditions: acromegaly, neuroendocrine tumors
ICD codes: E22.0, C7A.1, C7A.8, C7B.8, D3A.8
Drugs: octreotide fluidcrystal® injection depot
SMILES: [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

        Acromegaly:

          -  Male or female patients ≥18 years of age

          -  Acromegaly currently treated with Sandostatin LAR

        NET:

          -  Male or female patients ≥18 years of age

          -  Functional, well-differentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid
             syndrome (number of bowel movements and/or flushing)

          -  Currently treated with Sandostatin LAR for symptom control

        Exclusion Criteria:

        Acromegaly:

          -  Inadequate bone marrow function

          -  Abnormal coagulation or chronic treatment with warfarin or coumarin derivates

          -  Impaired liver, cardiac and/or renal function

          -  Known gallbladder, bile duct disease or pancreatitis

          -  Diabetes with poorly controlled blood glucose levels despite adequate therapy

          -  Hypothyroidisms not adequately treated

        NET:

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma,
             goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine
             carcinoma and small cell carcinoma

          -  Carcinoid syndrome refractory to treatment with conventional doses of somatostatin
             analogues (SSAs)

          -  Inadequate bone marrow function

          -  Abnormal coagulation or chronic treatment with warfarin or coumarin derivates

          -  Impaired liver, cardiac and/or renal function

          -  Known gallbladder, bile duct disease or pancreatitis

          -  Short-bowel syndrome

          -  Diabetics with poorly controlled blood glucose levels despite adequate therapy

          -  Hypothyroidism, not adequately treated
Clinical trial NCT02299635 (phase 2, status: terminated)
Conditions: triple negative breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pf-03084014, pf-03084014, pf-03084014
SMILES: CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C
Reason stopped: 
    the study was terminated on june 24th, 2015 due to change in strategy of pf-03084014
    development. there were no safety/efficacy concerns behind the decision.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of triple negative breast cancer (TNBC) with
             evidence of a) metastatic or b) locally recurrent advanced disease that is not
             amenable to resection or radiotherapy with curative intent.

          -  Availability of an original diagnostic tumor tissue or the most recent metastatic
             tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for
             Notch receptors genomic profiling

        Exclusion Criteria:

          -  Known brain metastases.

          -  Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
Clinical trial NCT02300103 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel, rbv
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  HCV genotype determined by the Central Laboratory

          -  HCV RNA > LLOQ at screening

          -  Participated and completed a Gilead sponsored HCV treatment study of direct acting
             antiviral (DAA) containing regimens.

          -  Male and female of childbearing potential must agree to use protocol specified
             method(s) of contraception

        Key Exclusion Criteria:

          -  Current or prior history: Clinically-significant illness (other than HCV) or any other
             major medical disorder that may interfere with treatment, assessment or compliance
             with the protocol; individuals currently under evaluation for a potentially
             clinically-significant illness (other than HCV) are also excluded.

          -  Screening ECG with clinically significant abnormalities

          -  Laboratory results outside of acceptable ranges at screening

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02301143 (phase 2, status: completed)
Conditions: pancreatic neoplasms
ICD codes: C25.3
Drugs: nab-paclitaxel, gemcitabine, chemoradiation, capecitabine
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Non- metastasis, unresectable, adenocarcinoma pancreatic cancer patients

          -  No prior anticancer therapy for pancreatic cancer

             •≥ 18 years of age with a performance status of 0 or 1•Adequate complete blood counts,
             hepatic function, and renal function

          -  Signed informed Consent

        Exclusion Criteria:

          -  Active bacterial, viral, or fungal infection

          -  Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV)
             infection, or receiving immunosuppressive or myelosuppressive

          -  Subjects with sensory neuropathy, ascites, or plastic biliary stent.

          -  Serious medical risk factors involving any of the major organ systems, or serious
             psychiatric disorders (including but not limited to connective tissue disorders, lung
             disease, and cardiac or seizure disorders)

          -  Women who are pregnant or breast feeding
Clinical trial NCT02301481 (phase 2, status: completed)
Conditions: stomach neoplasms, neoadjuvant therapy, chemoradiotherapy, chemotherapy
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5, D61.810, Z51.11, D64.81, D70.1, Z92.21, P04.11, T80.810S
Drugs: s-1, sox
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven locally advanced gastric adenocarcinoma in
             patients staged as cT3-4N0M0 or anyTN+M0

          -  No distant metastasis in liver,lung,bone,central nervous system(CNS),no peritoneal
             transplantation

          -  No prior abdominal or pelvic radiotherapy

          -  Karnofsky performance status(KPS)≥ 70, predictive life span no less than 6 months

          -  Patients must have normal organ and marrow function as defined below: Leukocytes:
             greater than or equal to 3,000 G/L; Platelets: greater than or equal to 100,000/mm3
             .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal
             institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit;
             Creatinine within normal upper limits

          -  Informed consent

        Exclusion Criteria:

          -  Any prior chemotherapy or other cancer treatment prior to this protocol

          -  Patients with other cancer history except cervical carcinoma in situ and non-malignant
             melanoma skin cancer

          -  With any distant metastasis in liver,lung,bone,CNS,or peritoneal transplantation

          -  History of allergic reactions attributed to similar chemical or biologic complex to
             S-1 or Xeloda or Oxaliplatin

          -  Uncontrolled illness including, but not limited to, active infection, symptomatic
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

          -  History of myocardial infarction within the past 6 months or history of ventricular
             arrhythmia

          -  History of prior radiation to the abdomen

          -  Pregnant or lactating females
Clinical trial NCT02301611 (phase 2, status: active, not recruiting)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: tlpldc, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0,1 (Appendix D)

          -  AJCC stage III or IV completely resectable melanoma identified before surgery

          -  Approximately 1 mg (1 cm3) of accessible and dispensable tumor that will not interfere
             with pathologic staging

          -  Clinically disease-free after surgery

          -  Completing SoC adjuvant therapy per NCCN guidelines to include chemotherapy, radiation
             therapy, and/or biologic therapy as clinically indicated. (Consent #2 should be signed
             as close to completion of SoC as possible but may overlap completion by up to one
             month.)

          -  Vaccinations initiated between 3 weeks and 3 months from completion of SoC
             multi-modality cancer care

          -  Adequate organ function as determined by the following laboratory values:

          -  ANC ≥ 1,000/μL

          -  Platelets ≥ 75,000/μL

          -  Hgb ≥ 9 g/dL

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN) or Creatinine clearance ≥ 50%

          -  Total bilirubin ≤ 1.5 ULN

          -  ALT and AST ≤ 1.5 ULN

          -  For women of child-bearing potential, agreement to use adequate birth control
             (abstinence, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, oral
             contraception, IUD, or use of condoms or diaphragms)

          -  Signed informed consent

        Exclusion Criteria:

          -  Evidence of residual disease after surgery and SoC adjuvant therapies

          -  Insufficient tumor available to produce vaccine

          -  ECOG >2 performance status (Appendix D)

          -  Immune deficiency disease or known history of HIV, HBV, HCV

          -  Receiving immunosuppressive therapy including chronic steroids, methotrexate, or other
             known immunosuppressive agents

          -  Pregnancy (assessed by urine HCG)

          -  Breast feeding

          -  Active pulmonary disease requiring medication to include multiple inhalers (>2
             inhalers and one containing steroids)

          -  Involved in other experimental protocols (except with permission of the other study
             PI)